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The aim of this study was to determine antimicrobial susceptibility of Pseu-
domonas aeruginosa strains to marbofl oxacin and gentamicin, and investigate the 
possible synergistic, additive, indifferent or antagonistic effects between the two 
agents. P. aeruginosa strains can develop resistance quickly against certain antibiot-
ics if used alone, thus the need emerges to fi nd synergistic combinations. A total of 
68 P. aeruginosa strains isolated from dogs were examined. In order to describe 
interactions between marbofl oxacin and gentamicin the checkerboard microdilution 
method was utilized. The MICs (minimum inhibitory concentrations) for marbo-
fl oxacin and gentamicin were in the range 0.25–64 mg/L and 0.25–32 mg/L, respec-
tively. The combination of marbofl oxacin and gentamicin was more effective with a 
MIC range of 0.031–8 mg/L and a MIC90 of 1 mg/L, compared to 16 mg/L for mar-
bofl oxacin alone and 8 mg/L for gentamicin alone. The FIC (fractional inhibitory 
concentration) indices ranged from 0.0945 (pronounced synergy) to 1.0625 (indif-
ference). Synergy between marbofl oxacin and gentamicin was found in 33 isolates. 
The mean FIC index is 0.546, which represents a partial synergistic/additive effect 
close to the full synergy threshold. In vitro results indicate that marbofl oxacin and 
gentamicin as partially synergistic agents may prove clinically useful in combina-
tion therapy against P. aeruginosa infections. Although marbofl oxacin is not used in 
the human practice, the interactions between fl uoroquinolones and aminoglycosides 
may have importance outside the veterinary fi eld.
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Introduction
Pseudomonas aeruginosa is a frequently isolated Gram-negative bacteri-
um in veterinary practice, associated mainly with external otitis, deep pyoderma, 
keratoconjunctivitis, respiratory and urinary tract infections [1, 2]. This bacteri-
um can develop resistance rapidly against several antibiotics, even during the 
course of antimicrobial treatment [3, 4]. Pandrug-resistant strains not susceptible 
to any of these substances have also been reported in the human medicine [5]. 
Accordingly, synergistic combinations of antibiotics are used frequently to elim-
inate this pathogen in human and veterinary practice alike. It was presented that 
synergism exists between enrofl oxacin and gentamicin in 5 P. aeruginosa strains 
[6].
Marbofl oxacin is a second generation fl uoroquinolone with marked effi -
cacy against P. aeruginosa. It has better activity [2, 7, 8] and a longer postantibi-
otic effect against the pathogen compared to enrofl oxacin [9]. 91.3% incidence of 
sensitivity to marbofl oxacin was reported in Pseudomonas spp. isolated from 
dogs was proven [10]. 183 P. aeruginosa strains isolated from the outer ear canal 
of dogs were investigated and they found that 93.4% were sensitive to marbo-
fl oxacin [11]. 26.1% resistance ratio was reported [1] in P. aeruginosa strains 
isolated from otitis cases in dogs and cats. Our previous study indicated 23% re-
sistance and 16% moderate susceptibility ratio among 56 isolates [12]. These data 
show an increasing tendency of marbofl oxacin resistance among P. aeruginosa 
strains in companion animals.
Gentamicin is an aminoglycoside frequently used in veterinary medicine. 
It is applied as a topical medication in dermatology or given parenterally for res-
piratory, urinary or systemic P. aeruginosa infections. 65.2% incidence of sus-
ceptibility [10] was reported to gentamicin in Pseudomonas spp. isolated from 
chronic otitis externa cases in dogs. 183 P. aeruginosa strains isolated from the 
outer ear canal of dogs [11] were investigated; 83.1% of the strains were suscep-
tible to gentamicin. Similar results [13] were reported, 84.6% of the investigated 
39 P. aeruginosa strains were sensitive to gentamicin.
The aim of our study was to determine antimicrobial susceptibility of 
P. aeruginosa strains to marbofl oxacin and gentamicin and investigate the pos-
sible synergistic, additive, indifferent or antagonistic effect between the two an-
tibacterial agents with special emphasis on those strains that were resistant to 
each antibiotic monotherapy.
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Materials and Methods
Bacteria involved in the study
A total of 68 P. aeruginosa strains isolated from dogs showing the clinical 
signs of otitis externa were used in this study. Acquired P. aeruginosa strains 
were grown on MacConkey agar and were identifi ed by Gram staining, micro-
scopic examination, growth in selective cetrimide agar (Sharlau Chemie, Sent-
menat, Spain), colony morphology, pigment production and oxidase positivity. 
The strains were collected and stored at –80 °C in Mueller–Hinton broth (Biolab 
Ltd., Budapest, Hungary) supplemented with 20% sterile glycerol. Isolates were 
subcultured on 5% sheep blood agar plates directly before the investigation. 
A reference strain of P. aeruginosa (ATCC No. 27853) was used as quality con-
trol in consonance with Committee of Laboratory Standards Institute (CLSI) 
guidelines [14].
In vitro susceptibility tests
The broth microdilution method was performed in accordance with CLSI 
guideline M7-A7 with a twofold dilution in 96-well sterile microtiter trays. For 
the determination of MICs (minimum inhibitory concentrations) for the single 
antibiotics, fi nal concentrations of marbofl oxacin or gentamicin in the wells were 
set to 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125 and 0.063 mg/L in Mueller–Hinton 
broth.
Bacteria grown for 24 hours in Mueller–Hinton broth were centrifuged at 
3000 g for 10 min. The bacteria were washed and resuspended in physiological 
saline. The optical density of the suspension at 600 nm was set to 0.1 with the 
appropriate amount of physiological saline, that corresponded to 108 colony form-
ing units (CFU) per mL. P. aeruginosa strains were diluted and distributed into 
the microtiter wells to achieve approximately a 105 CFU/mL bacterial density. 
The inoculated trays were incubated for a period of 24 h at 37 °C and evaluated 
with the unaided eye. Data were reported as MIC ranges and MIC at which 90% 
of the strains were inhibited (MIC90). Resistance threshold was determined 
 according to CLSI and EUCAST (European Committee of Antimicrobial Sus-
ceptibility Testing) breakpoints. Isolates having MIC values of 4 mg/L or higher 
for marbofl oxacin, and 8 mg/L or higher for gentamicin, were considered resist-
ant. When evaluating the combination, the lower threshold was used.
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Investigating antibiotic synergy
In order to describe interactions between marbofl oxacin and gentamicin, 
the checkerboard microdilution method was utilized [15, 16] for determining the 
lowest fractional inhibitory concentration (FIC) index [17]. Similar to the single 
antibiotic susceptibility tests, P. aeruginosa strains were distributed in the micro-
titer wells to achieve a 105 CFU/mL bacterial density. The inoculated trays were 
incubated for 24 h at 37 °C. The combined effects of the antibiotics were evalu-
ated as synergy, addition, indifference, and antagonism. To evaluate these inter-
actions, the values for marbofl oxacin (FICM) and gentamicin (FICG) were deter-
mined at each dilution.
FICM= MICM combination / MICM alone
FICG= MICG combination / MICG alone
The FIC indices were calculated for each strain according to the method of 
Elioponlos and Moellering [15] as FICindex = FICM+FICG and the results were in-
terpreted as follows: synergy (<0.5), partial synergy/addition (0.5–1.0), indiffer-
ence (1.0–4.0), and antagonism (>4.0). Mean FICindex was calculated to analyse 
the interactions for all investigated bacteria (n = 68) as
Mean FICindex = ∑ FICindex / 68.
In addition, data was also illustrated on isobolograms to confi rm and 
 analyse interactions between marbofl oxacin and gentamicin. The isobologram, 
a graph of equally effective dose pairs, is a commonly used method to describe 
drug synergism. In these graphs, the MIC values of the single drugs and the 
 different ratio combinations are plotted as axial points in a Cartesian plot. The 
straight line connecting MICmarbofl oxacin and MICgentamicin are those dose pairs that 
will produce an additive effect [18]. Effective dose pairs found below the additive 
line are considered synergistic combinations, when confi rmed with regression 
analysis.
Results
The sensitivity of the investigated P. aeruginosa strains to the two investi-
gated antimicrobials applied as a single treatment varied within broad limits 
( Table I). The MICs for marbofl oxacin and gentamicin ranged from 0.25–64 
mg/L and 0.25–32 mg/L, respectively. Three strains were resistant to both anti-
microbials alone, but two of these isolates were susceptible to the combination. 
The reference strain (ATCC No. 27853) showed MICs of 2 mg/L for marbofl oxa-
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cin as well as gentamicin. With respect to CLSI and EUCAST breakpoints, the 
ratio of resistant strains was 36.8% and 10.3% for marbofl oxacin and gentamicin, 
respectively.
Four gentamicin resistant strains were sensitive and 3 strains were resist-
ant to marbofl oxacin, of which 2 proved to be susceptible to the combination 
(Table II).
Regarding the combination, the FIC indices ranged from 0.0945 (pro-
nounced synergy) to 1.0625 (indifference). Additive and indifferent interactions 
were observed in 31 and 4 strains, respectively. Synergy between marbofl oxacin 
and gentamicin was found in 33 isolates, while no antagonistic effect was ob-
served in any of the strains. Taking into account the FIC indices acquired with 
the checkerboard method and isobologram analysis, the 1:1 ratio of the antimicro-
bials proved to be the most effective. The feature of this fi xed ratio combination 
is its much better activity against P. aeruginosa with a MIC range of 0.031–8 
mg/L and a MIC90 of 1 mg/L compared to the 16 and 8 mg/L values for marbo-
fl oxacin and gentamicin alone, respectively. Only 1 strain (1.5%) was resistant to 
the combination. The mean FIC index for the investigated P. aeruginosa strains 
was 0.546, which represents a partial synergistic/additive effect close to the full 
synergy threshold. The isobolograms acquired were convex without any excep-
tion, showing no antagonistic effect between the two antimicrobials in any of the 
isolates (Fig. 1).
Discussion
Multidrug resistant and extensively drug-resistant P. aeruginosa strains 
became abundant in the last decades in Europe and cause frequent therapeutic 
failure in veterinary and human practice [5, 19]. Taking into account the low per-
meability of the cell wall and the presence of effl ux pumps [20], the broad range 
of β-lactamases produced, biofi lm production [21], and the high genetic versatil-
ity of this species, only a very limited number of antimicrobials are at the clini-
cians disposal. Enrofl oxacin and marbofl oxacin are licensed only for veterinary 
use, the latter being more active against P. aeruginosa [2, 8]. A total of 349 
P. aeruginosa strains isolated from dogs and cats were investigated [8], 23% of 
these proved to be resistant to marbofl oxacin, a lower ratio compared to our 
 results (36.8%). Regarding gentamicin, Martin Barrasa et al. [10] reported 65.2% 
incidence of susceptibility to the aminoglycoside among Pseudomonas spp. iso-
lated from chronic otitis externa cases in dogs. The 83.1% of 183 P. aeruginosa 
strains were found susceptible to gentamicin [11]. In our study 89.7% of the iso-
lates were susceptible to gentamicin. There were 3 gentamicin resistant strains 
that were also resistant to marbofl oxacin. Two of these strains proved to be sus-
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ceptible to the marbofl oxacin: gentamicin combination and the MIC of the third 
strain was also decreased. Thus, those multiresistant strains resistant to the single 
antimicrobial therapy can be eliminated by the application of marbofl oxacin 
and gentamicin combination.
Resistance in Pseudomonas aeruginosa can develop even during therapy 
with most of the antimicrobials, including fl uoroquinolones [22, 23]. Multire-
sistant, extensively drug-resistant and panresistant strains of P. aeruginosa have 
already been reported, and a number of workers found that there is no sole anti-
microbial that has 100% activity against this bacterium [5, 24, 25]. An incidence 
of 39–42% multiresistant P. aeruginosa isolated from domestic animals between 
1989–1997 was reported [26]. In order to kill these multiresistant organisms and 
delay the development of resistance, a synergistic combination of two bacteri-
cidal antibiotics is often required as these might be able to break up resistance 
in the microorganism [27]. The combination of gentamicin and ciprofl oxacin 
 improved survival rate in postsurgical septicaemia in humans [28]. The in vitro 
interactions between enrofl oxacin and gentamicin in 7 P. aeruginosa strains 
were investigated [6]. The fl uoroquinolone and the aminoglycoside showed syn-
ergy in 5 and additive effect in 2 isolates.
The results of our study demonstrate synergy between marbofl oxacin and 
gentamicin in 33 (48.5%) isolates, addition and indifference in 31 (45.5%) and 
4 (6%) isolates, respectively. Analysing the FIC values in all of the isolates, 
the mean FIC index proved to be 0.546 that describes a partially synergistic effect 
of the combination. In the study of [6] the mean FIC value of 0.442 indicated 
Figure 1. Sample isobologram of marbofl oxacin and gentamicin in one P. aeruginosa strain. 
Convex curves (points below the additive line) indicate synergy, concave curves 
(points above the additive line) show antagonistic effect between two antimicrobials in a certain strain
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full synergy between enrofl oxacin and gentamicin. The reason of this differ-
ence compared to our results may be the lower activity of enrofl oxacin against 
P.  aeruginosa that could be enhanced signifi cantly by the addition of gentamicin, 
or just the small number of isolates examined.
The underlying mechanism of synergy between fl uoroquinolones and 
 aminoglycosides has not yet been elucidated. Fluoroquinolone resistance is at-
tributed to increased effl ux pump activity and/or chromosomal mutations in the 
gyrA or parC genes encoding DNA gyrase or topoisomerase IV [29]. Either of 
these changes can lead to low or high level resistance, and are frequently ob-
served together in resistant strains. As aminoglycosides cause misreading of the 
genetic code resulting in synthesis of mistranslated proteins, this phenomenon 
might infl uence effl ux pump activity and expression, leading to decreased sur-
vival in the presence of the antimicrobials. Although it might be plasmid encoded 
[30], fl uoroquinolone resistance is primarily chromosomal, while the genes en-
coding aminoglycoside modifying enzymes are usually found on plasmids [31]. 
Thus, plasmid and chromosomal resistance mechanisms are usually required 
jointly in a microorganism to achieve high level resistance to the combination of 
marbofl oxacin and gentamicin.
The usage of fl uoroquinolones in veterinary dermatology is recommended 
in those cases when susceptibility testing indicates that the pathogen is resistant 
to other classes of antimicrobials [32, 33]. Some authors would recommend sys-
temic usage of these antimicrobials instead of topical administration for treat-
ment of external otitis or pyoderma [34], however, a much higher concentration 
can be achieved with the latter method. As mentioned earlier, selection of resist-
ant organisms is much less likely when fl uoroquinolones are used in combination, 
as several mutation mechanisms should occur at the same time to achieve a high 
level resistance in P. aeruginosa that can lead to therapeutic failure. However, 
non-prudent use of fl uoroquinolones and consequent development of resistance 
may lead to public health risk as bacteria can be reservoirs of antibiotic-resistant 
bacteria [33, 35, 36].
In conclusion, full synergy has been found between marbofl oxacin and 
gentamicin in 48.5% of the P. aeruginosa strains investigated, with a mean FIC 
index of 0.546 indicating only partial synergy for all of the strains. The threshold 
of full synergy is at 0.5 FIC, and no antagonistic effect was observed in any of the 
strains, therefore, according to our results the justifi ed and targeted usage of the 
marbofl oxacin/gentamicin combination in infections caused by P. aeruginosa 
in the veterinary fi eld may yield benefi cial results, especially in topical products 
where the toxic effects of gentamicin might be negated if the tympanic mem-
brane is intact.
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